Brickell Biotech, Inc.
https://brickellbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Brickell Biotech, Inc.
Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
Finance Watch: With Four More IPOs, July May Match Or Exceed June’s 14
Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac had added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.
Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines
Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.
Coronavirus Update: Hardest Hit US States Will Test Moderna’s Vaccine
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Vical, Inc.
- Vical Incorporated (VICL)